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Neuroprotection and 
immunomodulation by 
xenografted human mesenchymal 
stem cells following spinal cord 
ventral root avulsion
Thiago B. Ribeiro1, Adriana S. S. Duarte1, Ana Leda F. Longhini1,2, Fernando Pradella2, 
Alessandro S. Farias2, Angela C. M. Luzo1, Alexandre L. R. Oliveira3 & 
Sara Teresinha Olalla Saad1
The present study investigates the effects of xenotransplantation of Adipose Tissue Mesenchymal 
Stem Cells (AT-MSCs) in animals after ventral root avulsion. AT-MSC has similar characteristics to 
bone marrow mesenchymal stem cells (BM-MSCs), such as immunomodulatory properties and 
expression of neurotrophic factors. In this study, Lewis rats were submitted to surgery for unilateral 
avulsion of the lumbar ventral roots and received 5 × 105 AT-MSCs via the lateral funiculus. Two 
weeks after cell administration, the animals were sacrificed and the moto neurons, T lymphocytes 
and cell defense nervous system were analyzed. An increased neuronal survival and partial 
preservation of synaptophysin-positive nerve terminals, related to GDNF and BDNF expression of 
AT-MSCs, and reduction of pro-inflammatory reaction were observed. In conclusion, AT-MSCs prevent 
second phase neuronal injury, since they suppressed lymphocyte, astroglia and microglia effects, 
which finally contributed to rat motor-neuron survival and synaptic stability of the lesioned motor-
neuron. Moreover, the survival of the injected AT- MSCs lasted for at least 14 days. These results 
indicate that neuronal survival after lesion, followed by mesenchymal stem cell (MSC) administration, 
might occur through cytokine release and immunomodulation, thus suggesting that AT-MSCs are 
promising cells for the therapy of neuronal lesions.
Research with embryonic and adult stem cells has been undertaken these past recent years and has been 
rendering interesting results in the field of regenerative medicine1. Mesenchymal stem cells (MSCs) may 
have a promising use in cellular therapies for various diseases: graft-versus-host disease (GVHD)2,3, auto-
immune diseases4,5 and neurological diseases6,7. Many studies have demonstrated the positive effect of 
MSCs in several animal models: autoimmune encephalomyelitis (EAE)8,9, diabetes10, cerebral ischemia11 
and spinal cord injuries12–14.
For clinical purposes, protocols have been designed for efficiently obtaining and using AT-MSCs15–17, 
however, there is a fundamental concern regarding the safety of the therapeutic use of MSCs for alloge-
neic transplantation. Studies using human MSCs in xenotransplant of several animal models may help 
clarify the functions and effects of these cells on a non-self-environment. Xenotransplantation is defined 
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by intraspecies and interspecies transplantation in immunocompetent animals with no immunosuppres-
sive drugs18. As this type of study raises many issues regarding functionality, durability and effects of 
MSCs in the animal’s body, the setting of safety standards is essential.
In the herein work, ventral root avulsion (VRA) at the spinal cord surface induced in Lewis rats, which 
mimics the brachial plexus injury in humans, was used to investigate the effects of human AT-MSCs 
xenotransplantation. In this model, injuries to spinal motor neurons in the interface between the central 
and peripheral nervous system result in a neuronal loss of up to 80% during the first two weeks19. The 
lesioned site becomes an inflammatory microenvironment favoring the sudden activation of resident 
glial cells, contributing to acute homeostasis changes and loss of synaptic inputs20. The lesion mimics the 
brachial plexus injury in humans, the most common avulsion injury resulting from motorcycle accidents, 
leading to motor, sensory or/and autonomic loss of the affected extremity21.
Despite MSCs differentiation capacity being well described in vitro, the paracrine action of AT-MSCs 
has been demonstrated in many intraspecies-transplantation models. Animal AT-MSC transplanted in 
cardiac repair models exhibited angiogenesis and reduction in cardiomyocyte apoptosis at the infarct 
border zone22. Lopatina et al. showed that transplanted cells induced nerve repair and growth via BDNF 
production following cell xenotransplantation in mice limb re-innervation-models23. Wei et al. further 
confirmed that medium secreted by AT-MSC avoided neuronal apoptosis, supporting the hypothesis 
that AT-MSC direct delivery could have therapeutic use in neurodegenerative disorders24,25. Treatment 
of experimental autoimmune diabetes suggests that AT-MSC transplantation could improve autoimmune 
diabetes pathogen by attenuating Th1 immune response simultaneous to Tregs expansion/proliferation26. 
Other authors have also shown the effects of AT-MSC xenotransplantation in several animal models: as 
promotion of angiogenesis and cell survival, immunosuppression effects and others14,27,28. Mesenchymal 
stem cells derived from adipose tissue (AT-MSCs) do not express major histocompatibility complex 
antigen II (MHC II)29 and might exert immunomodulatory action throughout cytokine release (TGF-β , 
HGF, prostaglandin E2 and other soluble factors)9,30–32 and indoleamine 2,3-dioxygenase (IDO)33. 
Mesenchymal stem cells(MSCs) have been used in clinical trial phase 1, establishing the safety of clin-
ical application of MSCs, however further modifications to improve MSCs efficacy are required18,34–37.
In this study, we aimed to verify whether human AT-MSCs exert neuroprotective and immunomod-
ulatory effects upon a xenograft model of ventral root avulsion (VRA). Our results demonstrated that 
human AT-MSCs locally suppress the rat immune system by reducing T cells and resident glia reactivity 
in the affected area and increase motor neuron survival through neuroprotective mechanisms.
Material and Methods
The methods described herein were carried out in accordance with the approved guidelines. The Ethics 
Committee of the Faculty of Medical Sciences and Institute of Biology of the University of Campinas 
approved all experimental protocols.
Isolation and culture of mesenchymal stem cells from adipose tissue (AT-MSCs). AT-MSCs 
cultures were established from AT obtained from seven healthy patients submitted to lipoaspiration 
procedures. All donors signed a free informed consent and all procedures were approved by the Ethics 
Committee of the Faculty of Medical Sciences, University of Campinas. AT-MSCs isolation was per-
formed as previously described38 and incubated in DMEM/ 10% FBS at 37 °C in a humidified atmos-
phere with 5% CO2. At 80% confluence, AT-MSCs were detached with 0.25% trypsin − 0.02% EDTA 
and replated at a lower density. All tissue culture reagents were purchased from InvitrogenTM Life 
Technologies – New York, NY.
AT-MSCs characterization and Qtracker labeling. At the third passage, immunophenotypical 
analysis of AT-MSCs-was performed using FITC-, PE-, or PECy5 – conjugated monoclonal antibodies 
(mAbs) against CD90, CD105, CD73, CD29, CD45, CD34, HLA-DR and HLA-ABC and their respective 
isotype control mAbs (BD Biosciences, Mountain View, CA, USA). Briefly, AT-MSCs were resuspended 
at a concentration of 106 cells/ml, incubated ABs at 4 °C for 30 min. AT-MSCs were then washed and 
analyzed by flow cytometry using FACS Calibur and CellQuest software (10.000 events/sample - BD 
Biosciences, San Jose, CA, USA). AT-MSCs were submitted to differentiation protocols for multi-potential 
differentiation capacity verification. AT-MSCs were cultured under specific differentiation medium for 21 
days and confirmed by specific cell staining for each differentiation (Table 1).
Prior to in vivo injection, AT-MSCs within 3–5 passages were marked with QTracker 655 (Invitrogen) 
according to the manufacturer’s protocol for cell identification and location after grafting.
RT-PCR. Gene expressions were detected by reverse transcriptase-polymerase chain reaction (RT-PCR). 
Total RNA was extracted from AT-MSCs with illustra RNAspin Mini isolation RNA Kit according to 
manufacturer’s protocol (GE Healthcare Life Siences - USA). Using total RNA as template, reverse tran-
scription reactions were performed with RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) 
using oligo dT-adaptador primer according to the manufacturer’s protocol. PCR amplification was then 
performed with 200 nM of primers for human TGF-β 1, HGF, IDO, GDNF, BDNF and β 2-microglobulin 
(Table  2). PCR cycles were: 94 °C for 5 minutes, (94 °C for 30 seconds, 55 °C for 30 seconds, 72 °C for 
45 seconds) × 35 cycles, 72 °C for 5 minutes. PCR products were analyzed by electrophoresis on 1.5% 
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agarose gel and image acquisition and data analysis were accomplished with Transluminator L-Pix 
(Loccus Biotecnologia).
Proliferative response of MBP-specific T lymphocytes. MBP-specific T lymphocytes (1 × 106, 
initial input) plus APCs from thymus were cultured in the presence of their specific antigen (10 μ g/ml) 
with or without AT-MSCs. After 3 days of culture, MBP-specific T lymphocytes were stained with trypan 
blue and counted in a TC10 automated cell counter (BioRad, USA).
Surgery, transplantation and cell tracing. Rats (n = 5) were subjected to unilateral avulsion of the 
lumbar ventral roots as previously described39. Immediately after injury (up to 5 minutes), QTracker655 
labeled AT-MSCs were placed directly into the lateral lesioned side funiculus (ipsilateral) in segments 
L4–L6 of the spinal cord at three equidistant points along the lesioned segment using a thick capillary 
Differentiation Medium Cell Staining
Osteogenic differentiation
DMEM (Invitrogen) Alizarin Red S
10% FBS (Invitrogen)
0.1 μ M dexamethasone (Sigma) (Sigma)
50 μ M ascorbate-2-phosphate (Sigma)
10 mM beta-glycerophosphate (Sigma)
Adipogenic differentiation
DMEM Oil-Red O
10% FBS
0.5 mM isobutylmethylxanthine (IBMX 
- Sigma) (Sigma)
1 μ M dexamethasone (Sigma)
10 μ M insulin (Sigma)
200 μ M indomethacin (Sigma)
Condrogenic differentiation
DMEM Syrus red, resorcin and fuchsin
100 ng/ml transforming growth factor - 
β 3 (TGF-β 3 - Peprotech)
100 nM sodium pyruvate (Sigma)
1 mM of dexamethasone (Sigma) (Sigma)
50 nM of ascorbic acid (Sigma)
0.5X insulin-transferrin-selenium A 
(ITS-A - Invitrogen)
0.,2% human albumin (Sigma)
Table 1.  Differentiation Medium and Cell Staining.
Gene Sequence
Product 
length
BDNF
FW: 5′ GGGCAAACACTGCATGTCTCTGGT 3′ 
131
RV: 5′ TCCAGGCCATTCTGCAGGGTCA 3′ 
GDNF
FW: 5′ CGCCCTTCGCGCTGAGCA 3′ 
145
RV: 5′ CGCTCTCTTCTAGGAAGCACTGCCA 3′ 
TGF-β 1
FW: 5′ GCGTGCTAATGGTGGAAACC 3′ 
100
RV: 5′ GCTTCTCGGAGCTCTGATGTG 3′ 
HGF
FW: 5′ TGACTCCGAACAGGATTCTTTCA 3′ 
101
RV: 5′ GCAGGGCTGGCAGGAGTT 3′ 
IDO1
FW: 5′ TTGGAGAAAGCCCTTCAAGTG 3′ 
100
RV: 5′ TGCCTT TCCAGCCAGACA A 3′ 
Β 2-Microglobulina
FW: 5′ ATGTCTCGCTCCGTGGCCTTAGCT 3′ 
375
RV: 5′ CCTCCATGATGCTGCTTACATGTC 3′ 
Table 2.  Primers for PCR.
www.nature.com/scientificreports/
4Scientific RepoRts | 5:16167 | DOi: 10.1038/srep16167
Pasteur pipette coupled to a Hamilton syringe (Supplement Fig. 1A). The spinal cord was then replaced 
in its original position and musculature, fascia and skin sutured in layers.
Animals were sacrificed 14 days after surgery and fixed by vascular perfusion with 4% formaldehyde 
in phosphate buffer (pH 7.4). Lumbar enlargement was then dissected, post-fixed overnight in the same 
fixative and frozen. Cryostat transverse sections (12 μ m) of spinal cords were obtained and transferred 
to silane-coated slides.
Neuronal survival. Images for counting neurons were acquired by Nikon Eclipse E600 microscope 
equipped with light, epifluorescence illumination and high-resolution CCD camera (RT Slider, Diagnostic 
Instruments, Inc., Sterling Heights, MI, USA) and PC running Image-Pro software (Media Cybernetics, 
Inc., Silver Spring, MD, USA). Silane-coated slides were stained for 5 to 10 min in an aqueous 1% cresyl 
fast violet solution at 45 °C. Sections were then washed in distilled water and mounted in glycerol/PBS 
mixture (3:1).
Motor neurons were identified based on their morphology and location in the ventral horn (dorsolat-
eral lamina IX). Only cells with a visible nucleus and nucleolus were counted. Counts were carried out on 
20 sections (every fourth section) along the lumbar enlargement both on the ipsilateral and contralateral 
sides of each rat (n = 5). The absolute numbers of motor neurons on the lesioned and non-lesioned sides 
per section, respectively, were used to calculate the surviving cell percentage in each specimen. To correct 
for double counting of neurons, Abercrombie’s formula40 was used; N = nt/(t + d), where N is the cor-
rected number of counted neurons, n is the counted cell number, t is the section thickness (12 μ m) and d 
is the average cell diameter. As size difference significantly affects cell counts, d was calculated specifically 
for each experimental group (ipsilateral and contralateral). In this regard, the diameter of the 15 ran-
domly picked neurons from each group was measured (ImageTool software, version 3.00, The University 
of Texas Health Science Center Santo Antonio, USA) and the mean value calculated, as shown in Table 3.
Immunohistochemistry. Primary anti-synaptophysin (1:200, Dako, Glostrup, Denmark), primary 
Anti-IBA1 (1:600, Wako, Osaka, Japan), primary anti-GFAP (1:100, Santa Cruz, Santa Cruz, CA, USA) 
and CD3-PE (1:200, Santa Cruz, Santa Cruz, CA, USA) were used to analyze synaptic covering, microglia 
activation, astroglial reaction and lymphocytes within the motor nucleus.
Primary and conjugated antibodies were diluted in a BSA and Triton x-100 in 0.01 M PBS solu-
tion. Sections were incubated overnight at 4 °C in a moist chamber. For primary AB, after rinsing in 
0.01 M PBS, the sections were incubated with a Cy2-conjugated secondary antiserum (1:250, Jackson 
Immunoresearch, West Grove, PA, USA) for 45 min in a moist chamber at room temperature. Sections 
were then rinsed in PBS, mounted in glycerol/PBS mixture (3:1), and images were generated using a con-
focal laser-scanning microscope (LSM 510 Carl Zeiss). For quantitative measurements, three representa-
tive images of the ipsi and contralateral ventral horn were captured from each animal for all experimental 
groups, totalizing 15 sampled images from each side per group. Quantification was performed with the 
enhanced contrast and density-slicing feature of IMAGEJ software (version 1.33 u, National Institutes of 
Health, USA). Integrated density of pixels was systematically measured in six representative areas of the 
lateral motor nucleus from each side (lesioned and non-lesioned sides), according to Oliveira et al.41. The 
lesioned/non-lesioned ratio of the integrated density of pixels was calculated for each section and then 
as the mean value for each spinal cord. CD3 (Lymphocyte marker) detection was performed in sections 
of rats (n = 3) and in regions of the spinal cord laminae in which AT-MSCs were not present, according 
to absence of qdot 655 fluorescence.
Statistical analysis. Data were analyzed using a two-tailed Student t test for parametric data or a 
two- tailed Mann–Whitney U test for non-parametric data at p < 0.05 (*), p < 0.01(**) and p < 0.001 
(***). Data were presented as mean ± standard deviation (SD).
Results
Mesenchymal Stem Cell Characterization. AT-MSCs antigen surface characterization was per-
formed by flow cytometry (FACS) using a panel of antibodies. At the fourth passage, cells were plastic 
Experimental Groups
Treated (n = 5) Non-treated (n = 5)
Ipslateral Contralateral Ipslateral Contralateral
Numbers of neurons per 
section 8.19 ± 2.10 14.04 ± 2.04 4.78 ± 1.31 13.71 ± 2.17
Numbers corrected by 
Abercrombie’s formulas 7.99 ± 2.,07 13.71 ± 1.97 4.74 ± 1.35 13.63 ± 2.30
Table 3.  Absolute mean number of neurons sampled per section in the ipsilateral and contralateral 
sides of the spinal cord in the different experimental groups (mean ± SD).
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adherent presenting fibroblastic morphology and positive for surface markers as CD90, CD105, CD73, 
CD29 and HLA-ABC, and negative for CD34, CD45 and HLA-DR (Supplement Fig. 2A).
To describe the plasticity attribute of AT-MSCs population (Supplement Fig. 2B), three differentiation 
protocols were performed. For osteogenic differentiation, cells were stained by Alizarin Red S, which 
shows calcium deposits (Supplement Fig. 2C). Cells submitted to adipogenic differentiation showed small 
red cytoplasmic vesicles, stained by Oil Red O, reflecting the accumulation of neutral lipids and triglyc-
erides in cytoplasmic vesicles of differentiated cells (Supplement Fig. 2D). AT-MSCs were induced into 
chondrogenic differentiation and differentiated cells produced glycosaminoglycan matrix stained with 
Alcian blue (Supplement Fig. 2E).
Cytokine expression and immunomodulatory action of AT-MSCs: in vitro proliferation assay 
of T Lymphocytes. Gene expression for neurotrophic factors (GDNF and BDNF) and immunosup-
pressive factors (TGF-β 1, HGF and IDO) were analyzed for each cell sample (AT-MSCs) obtained from 
seven donors by semi-quantitative RT-PCR (Reverse transcription-polymerase chain reaction) (Fig. 1A). 
The endogenous control was used in the reaction: β 2-microglobulin.Beta2-microglobulin gene tran-
scripts demonstrated that samples had a similar expression pattern. BDNF and GDNF transcripts were 
also observed to be strongly expressed as TGFβ 1 and HGF demonstrated that the expression of these 
genes maintained a similar level in all cell samples from different lipoaspirate tissue donors. IDO gene 
however, showed a variable expression level, suggesting that cell samples expressed the gene on a differ-
ent level.
TGFβ 1 and IDO expression by AT-MSCs suggested that these cells might present a tolerogenic func-
tion42. Therefore, we performed a T cell-specific proliferative assay to verify the influence of AT-MSCs 
over T cell activation and proliferation. Figure 1B shows that AT-MSCs reduced T cell specific prolifer-
ative response in a concentration dependent manner.
AT-MSCs Grafting in the VRA model and AT-MSCs immunomodulatory effect in rat spinal 
cord. AT-MSCs were labeled with qdot655 (Invitrogen) and injected into the lateral funiculus of the 
spinal cord after lesion (Supplement Fig. 1A). After two weeks, animals were sacrificed and serial histo-
logical sections along the lesion in the spinal cord were performed. Labeled qdot655 cells were detected 
at the site of injection (Supplement Fig. 1B–D) confirming that human AT-MSCs survived for at least two 
weeks in vivo. Nonetheless, AT-MSCs were not identified in the gray matter region nor had they migrated 
to surrounding spinal cord areas. AT-MSCs apparently remained near the injection site.
Figure 1. Immunosuppressive and neurotrophic major factors of AT-MSCs, during the 4th passage, 
and their in vitro effect on T cell proliferation. (A) Semi quantitative RT-PCR shows that AT-MSCs, 
from 7 donors, express mRNA immunosuppressive and neurotrophic factors as TGF-β 1, HGF, IDO, 
GDNF and BDNF. A 100 bp ladder is shown in the first lane, the reaction using water instead of DNA is 
in the second lane. cDNA of Daudi cells was used as control (C). (B) MBP-specific T lymphocytes (initial 
input = 1 × 106 T cells) plus Antigen Presenting Cells (APCs) from thymus were cultured in the presence 
of the myelin basic protein (MBP, black bar). Two different concentrations of AT-MSCs were added to the 
culture. Concentrations, 6 × 105 (grey bar) and 1.2 × 106 (white bar), induced a significant reduction in the 
proliferative response of MBP-specific T lymphocytes (n = 3).
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To investigate whether AT-MSCs had an in vivo paracrine immunomodulatory effect in the inflamed 
region, immunofluorescence with anti-CD3 was performed in regions of the spinal cord laminae in 
which AT-MSCs were not present, according to qdot 655 fluorescence absences. Excitingly, the CD3 
marker in the rat spinal region was weakly positive in animals treated with AT-MSCs (Fig.  2A,B). In 
untreated animals however, the CD3 marker was present throughout the ventral spinal cord, demon-
strating a strong T lymphocyte presence all along the affected area (Fig. 2B) and corroborating the T cell 
proliferation observed in the in vitro studies. Thus, the result suggests that AT-MSCs immunomodulatory 
profile acts upon the animal immune system decreasing inflammatory response.
Neuroprotective effect of AT-MSCs on motor neurons and synaptic activity. The neuroprotec-
tive effect of soluble factors, such as BDNF and GDNF, has been well described. Confirming these find-
ings, we showed that AT-MSCs expressed both factors (Fig. 1A). To quantify the protection of AT-MSCs 
treatment on motor neurons submitted to axotomy, the number of alpha motor neurons was counted 
on lesioned (Ipsilateral - IL) and non-lesioned (Contralateral - CL) sides of spinal cord, two weeks after 
avulsion (Fig. 3). No statistical differences were observed regarding the number of motor neurons on the 
Contralateral side of both groups (Table 1), and neuronal survival was represented as the percentage of 
the Contralateral side (Fig. 3B,D).
There was a greater number of surviving neurons with milder signs of chromatolysis in the treated 
group (Fig.  3A). Contrarily, there was intense motor neuron degeneration in the spinal cord motor 
nucleus of untreated animals (Fig. 3C), showing pyknotic nucleus and intense chromatolysis. Therefore, 
the number of surviving motor neurons on the ipsilateral was 50% higher for the treated than for the 
untreated group (treated = 56.25% ± 8.04; untreated = 36.66 ± 4.83%; mean ± SD; p = 0.0079; Fig. 3E).
For synaptic activity analysis after avulsion, immunostaining of the motor neuron body, using 
anti-synaptophysin antibody, was performed (Fig.  4). Synaptophysin expression was similar on the 
Contralateral sides of both groups (Fig.  4C,D,G,H,K,L). Motor neuron cell surface marker was well 
defined. There was an intense reactivity on the surface of Contralateral neurons, suggesting a large num-
ber of presynaptic inputs of alpha motor neurons (Fig. 4G,H). Intensity pixel analysis confirmed normal 
integrity of presynaptic inputs around motor neurons (Fig.  4K,L). Contrary to the Contralateral side, 
the intensity of synaptophysin expression on the Ipsilateral side was drastically reduced on the surface 
of the axotomized motor neurons of both groups (Fig. 4A,B,E,F,I,J). The synaptophysin expression how-
ever, was different between the groups (Fig. 4A,B). In treated animals, the motor neuron surface showed 
less reduction of pre-synaptic inputs compared to the untreated group (Fig. 4E,F), resulting in a reduc-
tion of the synaptic elimination process. (Treated group (Rt) = 0.772 ± 0.200, mean ± SD; Untreated 
group = 0.507 ± 0,143; p = 0.0015; Fig. 4M).
AT-MSCs Effects on Glial cells. Reactive astrogliosis and microglial activation were evaluated by 
anti-GFAP and anti-IBA1 staining respectively, two weeks after injury. There was a basal reactivity on 
the Contralateral side, in both groups, for both markers GFAP (astrocyte; Fig.  5) and IBA1 (micro-
glia; Fig.  6). As expected, after injury there was an increased activity of astrocyte and microglia on 
the Ipsilateral side (Fig.  5A,C; Fig.  6A,C) compared to the Contralateral side (Fig.  5B,D; Fig.  6B,D). 
Therefore, the intensity of both glial markers (GFAP and IBA1) was lower in the treated than in the 
untreated group. The analysis by pixel intensity graphically represents the similarity of the intensity of 
GFAP and IBA1 labeling of both Contralateral side (Fig. 5F,H; Fig. 6F,H) and highlights the difference 
Figure 2. Paracrine effects of AT-MSCs in vivo. (The chosen section was AT-MSCs-free, according to 
qdot labeling analysis). Treated group showed lower presence of T lymphocytes compared with non-treated 
animals in lesioned area. (A) Spinal cord of treated and non-treated group (5× ) (B) The section in both 
groups was marked with CD3 for Lymphocyte T detection and DAPI for nucleus detection (10× ).
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due to AT-MSCs treatment (Fig. 5E,G; Fig. 6E,G). Thus, AT-MSCs treatment reduced astrocyte (treated 
group = 1.227 ± 0.223, mean ± SD; untreated group = 1.870 ± 0.345; p = 0.0004; Fig.  5I) and microglia 
response to neuronal lesion (treated group = 2.697 ± 1.623, mean ± SD; untreated group = 5.094 ± 1.63
3p = 0.0032; Fig. 6I).
Discussion
Recent studies suggest stem cell feasibility for treating central nervous system (CNS) diseases and 
injuries43–45, thus, we herein proposed the administration of Adipose Tissue Mesenchymal Stem Cells 
(AT-MSCs) following ventral root avulsion (VRA) in a human/rat xenograft model. From an experi-
mental perspective, the possibility of using human stem cells in an animal model is a critical step before 
further clinical approaches, enabling the evaluation of possible immunoregulatory properties of these 
stem cells.
In the present study, AT-MSCs were extracted from lipoaspirate tissue treated by collagenase enzy-
matic digestion; the cells obtained were submitted to cell culture and characterization. AT-MSCs were 
adherent to plastic, they expressed CD90, CD73, CD105 and CD29 markers and lacked CD34, CD45 and 
Figure 3. Neuronal survival two weeks after VRA and AT-MSCs implant. (A–D) Representative images of 
motor neuron cell bodies in the nerve motor nucleus (10×). (A,C) Ipsilateral (IL) and (B–D) Contralateral 
(CL) sides of AT-MSCs treated and non-treated lesion, respectively (E) Percentage of spinal motor neuron 
survival after PBS and AT-MSCs treatment. After AT-MSCs treatment, a higher number of motor neurons 
were capable to survive in the lesion (**p < 0.01).
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HLA-DR markers. AT-MSCs were able to differentiate into three lineages (adipocytes, chondrocytes and 
osteocytes), according to MSC definition criteria46. Furthermore, transcripts showed neurotrophic factors 
(BDNF and GDNF) and anti-inflammatory cytokines (TGF-β 1, HGF and IDO1) expression. AT-MSCs 
immunomodulatory ability on in vitro proliferation of lymphocytes T was also observed. The main nov-
elty of this study is to show that human AT-MSCs prevent second phase neuronal injury, since they 
suppressed lymphocyte, astroglia and microglia effects, which finally contributed to rat motor-neuron 
survival and synaptic stability of the lesioned motor-neuron. Moreover, to our knowledge, our study 
showed, for the first time, the survival of the injected AT- MSCs for at least 14 days.
Fat tissue for mesenchymal stem cell acquisition is a good source of material for research and has 
a feasible potential for clinical use as human adipose tissue can easily be obtained in large quantities 
Figure 4. Representative image of synaptophysin immunolabelling in the spinal cord ventral horn after 
2 weeks of lesion. ((A) 10× ) The Ipsilateral (IL) of the treated group has stronger synaptophysin labeling 
than ((B) 10× ) the Ipsilateral of non-treated group. ((C,D) 10× ) The Contralateral of both groups showed 
similar synaptophysin immunolabeling pattern. (E–H) A representative motor neuron image analyzed by 
Start LSM Image Examiner (Carl Zeiss AIM Software) at zoom (5× ). On surface of motor neuron at (E) 
the Ipsilateral of the treated group, the synaptophysin immunolabeling are better p reserved when compared 
to (F) Ipsilateral non-treated-group moto neuron, but less preserved than the (G,H) Contralateral motor 
neuron of both groups. (I–L) The Integrated density of pixels obtained by Start LSM Image Examiner 
(Carl Zeiss AIM Software) emphasizes the difference among moto neurons. (M) Graph represents the 
quantification of the immunolabeling in all groups (**p < 0.01).
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and does not present some of the common problems, such as low harvested cell number and limited 
tissue amount47–49. The effects of AT-MSCs cell therapy has also proved to be very beneficial in several 
animal models22,50–53, although positive effects are probably more dependent on the cytokines produced 
by AT-MSCs than on their ability to differentiate into other cell lineages22,54. These properties are also 
applied to mesenchymal stem cells obtained from the bone marrow (BM-MSCs)50,55.
Several studies indicate that AT-MSCs modulate the immune system negatively. In multiple sclerosis 
mouse models (EAE), Constantin and colleagues56 found that AT-MSCs administration during the pre-
clinical phase of the disease exerted an anti-proliferative T lymphocyte effect. For type 1 diabetes model26, 
AT-MSCs treatment induced proliferation of regulatory T-cells, reducing Th1 and pro-inflammatory 
cytokine activity (IFN-γ , IL-2 and TNFα ), whereas there was an increase in anti-inflammatory cytokines 
after 35 days of treatment. Peng and colleagues57 performed experiments with AT-MSCs and dendritic 
cells subjected to co-culture with CD4+ T cells and the group demonstrated that co-stimulatory mole-
cules were downregulated (IL-12 and TNF); there was an increased IDO1 expression of dendritic cells 
and dendritic cells inhibited CD4+ T cells activation, confirming AT-MSCs immunomodulatory effect. 
Regarding human stem cell xenotransplant, review articles have shown that transplantation resulted in 
Figure 5. Representative image of Glial Fibrillary Acidic Protein (GFAP) in the spinal cord ventral horn 
after 2 weeks (10×). (A,C) The Ipsilateral of both groups has a stronger GFAP labeling than (B,D) the 
Contralateral. (A) The Ipsilateral of the treated group showed a distinguished reduction of astroglial reaction 
when compared to (C) non-treated group. (E–H) Integrated density of pixels, analyzed by Start LSM Image 
Examiner (Carl Zeiss AIM Software), points out the difference concerning to (E,G) Ipsilateral and (F,H) 
Contralateral of both groups and to Ipsilateral of (E) AT-MSCs and (G) PBS administration. (I) Graph 
represents the immunolabeling quantification in all groups (***p < 0.001).
Figure 6. Representative image of Microglial activation by labelling of Ionized calcium binding adaptor 
molecule 1 (IBA1) in the spinal cord ventral horn after 2 weeks (10×). (A,C) The Ipsilateral side of both 
groups showed a higher IBA1 labelling than (B,D) the Contralateral. (A) The Ipsilateral side of the treated 
group showed a reduction of microglial activation when compared to (C) non-treated group. Integrated 
density of pixels analyzed by Start LSM Image Examiner (Carl Zeiss AIM Software), points out the 
difference concerning to (E,G) Ipsilateral and (F,H) Contralateral sides of both groups and to Ipsilateral (E) 
AT-MSCs and (G) PBS administration. (I) Graph represents the immunolabeling quantification in all groups 
(**p < 0.01).
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positive action for 7 immunocompetent recipient animal species27,28, these results are also associated with 
the low or absent HLA-DR expression on MSC´s membrane surface.
MSCs immunomodulatory effects seem to be mediated, in part, by the secretion of IDO-1 and 
anti- inflammatory cytokine expression31,32, as IL-10, TGFβ and HGF by themselves. IDO and 
anti-inflammatory cytokine release, mainly IL-10 and TGFβ , may enhance cells with regulatory proprie-
ties diminishing the inflammatory response at the injury site42,58. Additionally, a number of studies have 
described the secretion of known neurotrophic factors by AT-MSCs, such as BDNF, GDNF, PDGF, FGF 
and others59–62, which lead to neuronal survival, axonal branching, synapse formation and differentiation 
of residing stem cells in the nervous system56. Thus, the main effects of AT-MSCs should occur through 
paracrine factor secretion. Despite the fact that the cells are localized at the injection site, as herein 
shown, we presume that the secretion of these factors by MSCs reaches the entire lesion area contributing 
to neuronal survival related to root avulsion.
Herein, human AT-MSCs immunomodulatory effect in a rat model (xenotransplantation) was 
observed. Human AT-MSCs were able to reduce in vitro T-lymphocyte proliferation, reduce in vivo 
T-cell activity in the injury area and survive for at least 14 days in the animal model (experimen-
tal period). Furthermore, in addition to HLA-DR absence on the surface of the cellular membrane, 
AT-MSCs expresses anti-inflammatory factors (TGFβ and HGF), and IDO1. T lymphocyte proliferation 
assay showed that the higher the AT-MSCs cell concentration, the lower T cell proliferation. Moreover, 
the presence of T lymphocyte (CD3) in the spinal cord section was reduced, suggesting that AT-MSCs 
acts through the paracrine effect, since the immunomodulatory action of these cells can also occur at 
a distance. Thus, results suggest that human AT-MSCs have a paracrine effect on the injured spinal 
cord microenvironment and the immunoregulatory effects of human AT-MSCs are apparently similar to 
animal AT-MSCs, when compared to other studies26,56,63. This is relevant clinical information for future 
allogeneic transplants.
Moreover, human AT-MSCs express neurotrophic factors, such as BDNF and GDNF, and the presence 
of these cells in the animal model may favor the survival of injured motor neurons, as in the control 
group most motor neurons had degenerated after 2 weeks. Furthermore, there was a reduction in astro-
gliosis and microglia activation, possibly reducing the effects of secondary damage caused by glial cells 
to motor neurons.
Despite GDNF effect being significantly more potent than BDNF in promoting axonal regeneration, 
the combined BDNF and GDNF treatment after tibial nerve section in adult rats has synergic effects 
and significantly increases the number of motor neurons that have regenerated their axons64. However, 
neurotrophic factors are not capable of maintaining the survival of affected motor neurons for long 
periods if there is no connection between the body and the target cell65. Thus, AT-MSCs therapy would 
be a strategy to allow neuronal survival and maintenance of spinal circuit (synaptophysin labelling pres-
ervation) for up to 2 weeks subsequent to root re-implantation.
Rodrigues and colleagues obtained similar results in a ventral root avulsion study after injection of 
allogeneic bone marrow MSCs (BM-MSCs)60, observing increased motor neurons survival, synaptic ves-
icle preservation and reactive astrogliosis reduction. In a comparative human AT-MSCs and BM-MSCs 
study in an animal model of spinal cord injury (SCI), Zhou and colleagues14 observed an increased 
angiogenesis at the lesion epicenter of the spinal cord, axonal recovery and reduction of inflammatory 
infiltrates, however the results were better for AT-MSCs treatment, also proving the human cell effects 
on the animal system and corroborating our results.
Despite our promising results, the development of a complete regenerative process and eventual 
recovery of the animal’s movements would necessarily involve re-implantation of avulsioned nerve roots. 
Recently, Espin and colleagues13 reported that root re-implantation combined with allogeneic injec-
tion of BM-MSCs had synergistic neuroprotective effects and increased growth of axonal regeneration. 
Therefore, further studies are required to assess the regenerative potential of avulsed motor neurons 
subjected to human AT-MSCs treatment and root re-implantation, as AT-MSCs appear to be a better 
source regarding abundance, accessibility and results.
Lastly, the present work combined morphological and immune evaluation of human AT-MSCs prop-
erties in an animal model of proximal lesion of spinal cord motor roots. Immunomodulatory effects 
showed to be combined with the neuroprotective profile of human AT-MSC, suggesting that the pro-
posed therapy is feasible in clinical studies for autologous and allogeneic stem cell injection.
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